Precision dermatology incorporates individualized dermatologic disease-directed targeted therapy (D3T2) for the management of dermatoses and includes important applications in the evaluation, diagnosis, prognosis, and therapy of patients with cutaneous malignancies. |
Patient-focused specific therapy is based on either biomarker profiles (derived from disease-related skin lesions or plasma) or genomic profiling of the tumor. |
Precision dermatology can be used to determine effective agents for patients with dermatoses such as psoriasis, atopic dermatitis, and prurigo nodularis. |
Precision dermatology can be used to evaluate the diagnosis and/or determine the treatment of not only melanoma and nonmelanoma [such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] cutaneous malignancies, but also rare cancers that originate or metastasize to the skin, such as perivascular epithelioid cell tumor (PEComa). |
Precision dermatology is the next therapeutic frontier for the treatment of patients with dermatologic conditions. |
Introduction
Methods
Compliance with Ethics Guidelines
Discussion
Psoriasis
Atopic Dermatitis
Prurigo Nodularis
Melanoma
2-GEP and 3-GEP Testing: Clinical Diagnosis
Test | Discriminating genes | Control genesa | References |
---|---|---|---|
2-gene expression profile | 2 genesb: LINC, PRAME | None | |
3-gene expression profile | 3 genesc: LINC, PRAME, TERT | None | |
10-gene expression profile | 8 genesd: CXCL8, GDF15, ITGB3, LOXL4, MLANA, PLAT, SERPINE2, TGFBR1 | 2 genese: B-actin, RLP0 | |
23-gene expression profile | 14 genesf: CCL5, CD38, CXCL9, CXCL10, IRF1, LCP2, PI3, PRAME, PTPRC, S100A7, S100A8, S100A9, S100A12, and SELL | 9 genesg: CLTC, MRFAP1, PPP2CA, PSMA1, RPL8, RPL13A, RPS29, SLC25A3, and TXNL1 | |
31-gene expression profile | 28 genesh: ARG1, AQP3, BAP1 (two gene loci: both the 3’ and 5’ ends), BTG1, CLCA2, CRABP2, CST6, CXCL14, DSC1, EIF1B, GJA1, ID2, KRT6B, KRT14, LTA4H, MGP, PPL, RBM23, ROBO1, S100A8, S100A9, SAP130, SPP1, SPRR1B, TACSTD2, TRIM29, and TYRP1 | 3 genesi: FXR1, HNRNPL, and YKT6 | |
35-gene expression profile | 32 genesj: ABLIM1, ANXA8L1, ATP6V0E2, BAP1, BCL2A1, BTG1, CLCA2, CST6, CSTA, CXCL14, DCT, DSP, DUSP4, GATA3, GJA1, GPR143, HAL, KLF5, KRT2, KRT17, MGP, NES, PPL, PTN, RPL37A, RPS16, S100A8, S100A9, SAP130, SFN, TP63, and WIPI1 | 3 genesi: FXR1, HNRNPL, and YKT6 |
23-GEP and 35-GEP Testing: Pathology Diagnosis
10-GEP and 31-GEP Testing: Prognosis
Basal Cell Carcinoma (BCC)
Squamous Cell Carcinoma (SCC)
Test | Discriminating genes | Control genesa | References |
---|---|---|---|
40-gene expression profile | 34 genesb: ACSBG1, ALOX12, APOBEC3G, ATP6V0E2, BBC3, BHLHB9, CEP76, DUXAP9, GTPBP2, HDDC3, ID2, LCE2B, LIME1, LOC100287896, LOC101927502, MMP10, MRC1, MSANTD4, NFASC, NFIC, PDPN, PI3, PLS3, RCHY1, RNF135, RPP38, RUNX3, SLC1A3, SPP1, TAF6L, TFAP2B, ZNF48, ZNF496, and ZNF839 | 6 genesc: BAG6, FXR1, KMT2C, KMT2D, MDM2, MDM4 |
Rare Cutaneous Tumors: Perivascular Epithelioid Cutaneous Tumor (PEComa)
Altered gene | Percent of patients with PEComa with altered genea (%) | Number of patients with PEComa with altered genea | Pathway activated | Drugs with an impact on target |
---|---|---|---|---|
TSC2 | 32.3 | 10 | mTOR | Sirolimus (rapamycin) Everolimus Temsirolimus |
TSC1 | 9.6 | 3 | mTOR | Sirolimus (rapamycin) Everolimus Temsirolimus |
TFE3 fusions | 16.1 | 5 | Unclear | None known |
FLCN | 6.4 | 2 | Unclear | None known |